Related Experiment Video
Updated: Jun 14, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
Published on: April 21, 2022
Treatment of lobar atelectasis with bronchoscopically administered recombinant human deoxyribonuclease in cystic
Anne Marie McLaughlin1, Emmet McGrath, Rupert Barry
1Department of Medicine and Therapeutics, St Vincent's University Hospital, Dublin 4, Ireland. annemmclaughlin@gmail.com
Introduction:
Recombinant human deoxyribonuclease (rhDNase) reduces sputum viscosity and improves pulmonary function in cystic fibrosis (CF).
Objective:
The objective of this study was to describe our experience in which rhDNase (Pulmozyme; Roche, Basel, Switzerland) was administered by bronchoscopic instillation into atelectatic lobes in five adults with CF.
Conclusion:
We found this method successful in treating lobar atelectasis, which was resistant to conventional therapy with antibiotics and physiotherapy. In all but one of the cases we described, administration of DNase in this manner resulted in a radiographic and clinical improvement of the atelectasis. We recommend that respiratory physicians consider this as a second line treatment in the management of atelectasis.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Pulmonary Cycle: Exhalation
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
